ABSTRACT
Objective Multiple myeloma (MM)-related morbidity has a profound effect on quality of life (QoL), and immune function, but few studies have prospectively examined the impact of COVID-19 pandemic and attendant vaccination on both immunity and QoL of patients with MM. We aimed to characterise these effects in a prospective cohort study.
Design We initiated a prospective national cohort study of patients with MM from start of the second wave of SARS CoV-2 infections in December 2020 and resultant COVID lockdown in the United Kingdom. We assessed current myeloma status, history of COVID19 symptoms, testing and vaccination including response using the rudystudy.org platform. In addition, healthcare resource use, mental and social well being and loneliness (Lubben scale) from the start of the COVID-19 pandemic were assessed.
Participants We report data from the first one hundred and nine adults with MM who completed the questionnaires and the first round of blood testing in the cohort.
Results Five patients (4.5%) had COVID-19 infection confirmed by history and/or testing (Nucleocapsid antibody). Up to 98% of patients shielded completely or partially during both waves of the pandemic, with 18% of patients consequently changing antimyeloma therapy in the shielding period. Using the Lubben scale, 21/99 (21.2 %) reported social isolation. Using HADS scale 23.1% of patients reported symptoms of mild to moderate anxiety or mild to moderate depression during this period. Humoral immune response (spike ab) tested 3 weeks after first vaccination was detected in 17/28 (60%) patients.
Conclusion Myeloma patients shielded during waves of the pandemic with significant change to therapy, low level natural COVID-19 infection (4%) and social isolation. Humoral response following the first dose of COVID-19 vaccine is lower than that reported in non-myeloma cohorts.
What is already known on this topic Limited published data exist on the effect of the COVID-19 pandemic on myeloma patients. Post first vaccine response in myeloma patients has been reported in a small number of patients from two studies ranging from 25 % to 56%.
What this study adds This study reports myeloma patients shielded during waves of the pandemic and demonstrates consequent significant social isolation and changes to therapy. Low level natural COVID-19 infection (4%) was noted in the study and humoral response following first dose of COVID-19 vaccine was lower than that reported in non-myeloma cohorts.
Competing Interest Statement
All authors completed the ICMJE disclosure form. The following personal or financial relationships relevant to this manuscript existed during the conduct of the study. MD reports shares in Abingdon Health. SM reports honoraria from Takeda, Janssen, Sanofi and Celgene. MD also reports advisory board from Takeda, Celgene, Janssen, Sanofi, Oncopeptide, Karyopharm and Amgen. DS reports honoraria for Abbvie, Jannsen and Takeda. GC reports honoraria from Celgene, Janssen, Takeda, Amgen, Roche, Sanofi, Onopeptides, Karyopharm and IQVIA. GC also reports research grant from Celgene, Takeda and IQVIA. NG reports horararia from Janssen and Amgen and research grant from Kyowa Kirin. KMJ reports honoraria, research grant and advisory board from Amgen, Janssen, Kyowa Kirin Hakin and UCB. KMJ is also the president of the Bone Research Society, Co-Chair of the Capture the Fracture Steering Committee in the International Osteoporosis Foundation. KR reports honoraria, research grant from Janssen, Celgene, Takeda and Amgen. He also reports advisory board from Celgene, Takeda, Janssen, Amgen, Abbvie, Sanofi, Oncopeptides, Karyopharm, GSK, Adaptive biotech, Pfizer and speakers bureau from Celgene, Takeda and Adaptive Biotech.
Funding Statement
Funding for this study has been received from Blood Cancer UK Consortium and Janssen UK. RUDY platform has been funded by NIHR.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is based on the existing RUDYstudy.org platform (LREC 14/SC/0126 & RUDY LREC 17/SC/0501), an established online rare disease platform with online dynamic consent and patient reported outcome assessments. Specific ethics amendment was sought for this project on 4th December 2020, and approved on 10th December 2020 by Berkshire B ethics committee (Ref 17/SC/0501). HRA approval and Ethics permission uploaded as supplementary files
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Patients have consented to anonymised data sharing for research and plublication purposes.
